A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20% advantage in the two-year OS rate for people with advanced melanoma who first received immunotherapy (72% survival rate) versus those who initially got targeted therapies (52% survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.
